Navigating AI risks in healthcare just got easier with the FDA’s new draft guidance and explanations from Guillaume Gigon, Innovaderm’s VP of Technology and AI.
You can even comment on the FDA draft document by April 7.
Navigating AI risks in healthcare just got easier with the FDA’s new draft guidance and explanations from Guillaume Gigon, Innovaderm’s VP of Technology and AI.
You can even comment on the FDA draft document by April 7.
Do not miss out on valuable insights and research updates. Join our scientific community today!
Fields marked with * are required.
